New study suggests J&J recipients should get booster shot to protect against Delta variant
Recipients of the one-shot Johnson & Johnson COVID-19 vaccine may need to get a second dose to protect against the Delta and Lambda coronavirus variants because its less effective against them, a new study suggests, per The New York Times.
"The message that we wanted to give was not that people shouldn't get the J&J vaccine, but we hope that in the future, it will be boosted with either one dose of J&J or a booster with [the Pfizer and Moderna COVID-19 vaccines]," Nathaniel Landau, a virologist at New York University's Grossman School of Medicine who led the study, told the Times.
The study, which has not been peer reviewed, involvded Landau and his team looking at blood samples taken from 17 people who had received both doses of the Pfizer and Moderna vaccines and 10 people with one dose of J&J. The J&J vaccine started out with a lower efficacy rate, which dropped more sharply against the variants, the Times reports. However, because the study was based on lab experiements, the Food and Drug Administration is unlikely to change its single-dose recommendation because of it, the Times notes. Further, seperate small studies published by researchers affialiated with J&J found that the vaccine's protection strengthened over time. Read more at The New York Times.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
ACA opens 2025 enrollment, enters 2024 race
Speed Read Mike Johnson promises big changes to the Affordable Care Act if Trump wins the election
By Peter Weber, The Week US Published
-
McDonald's sued over E. coli linked to burger
Speed Read The outbreak has sickened at least 49 people in 10 states and left one dead
By Rafi Schwartz, The Week US Published
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
By The Week UK Published
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US Published
-
Mpox: how dangerous is new health emergency?
Today's Big Question Spread of potentially deadly sub-variant more like early days of HIV than Covid, say scientists
By The Week UK Published
-
What is POTS and why is it more common now?
The explainer The condition affecting young women
By Devika Rao, The Week US Published
-
Brexit, Matt Hancock and black swans: five takeaways from Covid inquiry report
The Explainer UK was 'unprepared' for pandemic and government 'failed' citizens with flawed response, says damning report
By Harriet Marsden, The Week UK Published
-
Should masks be here to stay?
Talking Points New York Governor Kathy Hochul proposed a mask ban. Here's why she wants one — and why it may not make sense.
By Anya Jaremko-Greenwold, The Week US Published